Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Percutaneous Coronary Intervention
100%
ST Segment Elevation Myocardial Infarction
83%
Myocardial Infarction
75%
Rapamycin
65%
Cardiogenic Shock
58%
Drug-Eluting Stent
48%
Stent Thrombosis
39%
Primary Percutaneous Coronary Intervention
35%
Revascularization
35%
Optical Coherence Tomography
33%
Intravascular Ultrasound
33%
Coronary Artery Disease
31%
Diabetes
31%
Diabetes Mellitus
31%
Hazard Ratio
31%
Umirolimus
31%
Everolimus
26%
Target Lesion
23%
Acute Heart Infarction
22%
Coronary Angiography
22%
Target Lesion Revascularization
21%
Patient with Diabetes
20%
COVID-19
19%
Angiography
18%
Zotarolimus
18%
Acute Coronary Syndrome
17%
Heart Death
17%
Non ST Segment Elevation Myocardial Infarction
17%
Fractional Flow Reserve
16%
Major Adverse Cardiac Event
15%
Odds Ratio
14%
All Cause Mortality
14%
Diseases
13%
Cardiovascular System
13%
Cohort Analysis
12%
Coronary Artery
12%
Infarction
12%
Stable Angina Pectoris
11%
Stenosis
11%
Ischemic Heart Disease
10%
Out of Hospital Cardiac Arrest
10%
Apoplexy
10%
Paclitaxel
9%
Bleeding
9%
In-Stent Restenosis
9%
Thorax Pain
9%
Atrial Fibrillation
9%
Restenosis
9%
Noninferiority Trial
9%
Assisted Circulation
9%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Infarction
83%
ST Segment Elevation Myocardial Infarction
59%
Rapamycin
55%
Stent Thrombosis
44%
Umirolimus
35%
Cardiogenic Shock
35%
Coronary Artery Disease
34%
Acute Heart Infarction
23%
Heart Death
22%
Diabetes Mellitus
20%
Everolimus
17%
Diseases
17%
All Cause Mortality
17%
Cardiovascular Disease
12%
Ischemic Heart Disease
12%
Non ST Segment Elevation Myocardial Infarction
11%
Noninferiority Trial
11%
Cerebrovascular Accident
10%
Cohort Study
10%
Major Adverse Cardiac Event
10%
Acute Coronary Syndrome
9%
Stable Angina Pectoris
8%
Out of Hospital Cardiac Arrest
8%
Cardiovascular Risk
8%
CD34 Antibody
8%
Antiplatelet
8%
Zotarolimus
7%
Placebo
7%
Observational Study
7%
Mortality Rate
7%
Biological Marker
7%
Stenosis
7%
Congestive Heart Failure
6%
Randomized Clinical Trial
6%
Brain Ischemia
6%
Bleeding
6%
Atrial Fibrillation
6%
Paclitaxel
6%
Clopidogrel
5%
Coronary Artery Atherosclerosis
5%
Infarction
5%
Pandemic
5%
Nursing and Health Professions
Percutaneous Coronary Intervention
23%
ST Segment Elevation Myocardial Infarction
18%
Stent
17%
Confidence Interval
14%
Cardiogenic Shock
14%
Revascularization
11%
Coronary Angiography
10%
Drug Eluting Coronary Stent
10%
Clinical Outcome
9%
Heart Infarction
9%
Rapamycin
9%
Coronary Artery Disease
9%
Diabetes Mellitus
8%
Acute Heart Infarction
7%
Patient with Diabetes
6%
Hazard Ratio
6%
Umirolimus
5%